American Journal of Ophthalmology
Volume 147, Issue 6 , Pages 1022-1030.e5 , June 2009

Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study

  • Marco Bonini-Filho

      Affiliations

    • MacIma–Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, São Paulo, Brazil
    • Retina Section, Department of Ophthalmology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
    • ,
  • Rogério A. Costa

      Affiliations

    • MacIma–Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, São Paulo, Brazil
    • Retina Section, Department of Ophthalmology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
    • Corresponding Author InformationInquiries to Rogério A. Costa, MacIma–Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Rua Padre Duarte 989 apto 172, Araraquara SP 14801-310, Brazil
    • ,
  • Daniela Calucci

      Affiliations

    • MacIma–Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, São Paulo, Brazil
    • ,
  • Rodrigo Jorge

      Affiliations

    • Retina Section, Department of Ophthalmology, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil
    • ,
  • Luiz A.S. Melo Jr

      Affiliations

    • MacIma–Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, São Paulo, Brazil
    • ,
  • Ingrid U. Scott

      Affiliations

    • Departments of Ophthalmology and Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania

,Accepted 12 January 2009.

References 

  1. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, IV: diabetic macular edema. Ophthalmology. 1984;91:1464–1474
  2. Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS Report No. 1. Arch Ophthalmol. 1985;103:1796–1806
  3. Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: ETDRS Report No. 4. Int Ophthalmol Clin. 1987;27:265–272
  4. Early Treatment of Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS Report No. 9. Ophthalmology. 1991;98:766–785
  5. Early Treatment of Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema: Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19. Arch Ophthalmol. 1995;113:1144–1155
  6. Early Treatment of Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms: ETDRS Report No. 11. Ophthalmology. 1991;98:807–822
  7. Ticho U, Patz A. The role of capillary perfusion in the management of diabetic macular edema. Am J Ophthalmol. 1973;76:880–886
  8. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445–450
  9. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–1039
  10. Murata T, Nakagawa K, Khali A, et al. The relation between expression of vascular endothelial growth factor and breakdown of the blood retinal barrier in diabetic rat retina. Lab Invest. 1996;74:819–825
  11. Amin RH, Frank RN, Kennedy A, et al. Vascular endothelium growth factor is present in glial cels of the retina and the optic nerve of human subjects with non-proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:36–47
  12. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70–77
  13. Funatsu H, Yamashita H, Ikeda T, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol. 2002;133:537–543
  14. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690–1696
  15. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806–816
  16. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2006;113:294–301
  17. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961–969
  18. Gragoudas ES, Adamis AP, Cunningham ET, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816
  19. Cunningham ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005;112:1747–1757
  20. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36:331–335
  21. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336–339
  22. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400
  23. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  24. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  25. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: Automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci. 2004;45:2399–2406
  26. Costa RA, Skaf M, Melo LA, et al. Retinal assessment using optical coherence tomography. Prog Retin Eye Res. 2006;25:325–353
  27. Sternberg P, Fitzke F, Finkelstein D. Cyclic macular edema. Am J Ophthalmol. 1982;94:664–669
  28. Frank RN, Schulz L, Abe K, Iezzi R. Temporal variation in diabetic macular edema measured by optical coherence tomography. Ophthalmology. 2004;111:211–217
  29. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363–372
  30. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279–284
  31. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495–511
  32. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1–9
  33. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci. 2006;47:4569–4578
  34. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina. 2007;27:141–149
  35. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275–278
  36. Bakri SJ, Donaldson MJ, Link TP. Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab. Eye. 2006;20:1474–1475
  37. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. 2006;26:699–700
  38. Mason JO, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142:685–688
  39. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695.e1–1695.e15
  40. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999–1005
  41. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBePe study). Retina. 2006;26:1006–1013
  42. Neubauer AS, Kook D, Haritoglou C, et al. Bevacizumab and retinal ischemia. Ophthalmology. 2007;114:2096
  43. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology. 2008;115:1447–14491449.e1–10

 Supplemental Material available at AJO.com.

PII: S0002-9394(09)00044-0

doi: 10.1016/j.ajo.2009.01.009

American Journal of Ophthalmology
Volume 147, Issue 6 , Pages 1022-1030.e5 , June 2009

Article Tools

* Image Usage & Resolution